ANX009

BIOLOGICAL2 trials

Sponsors

Annexon, Inc.

Conditions

Lupus NephritisSafety and Tolerability in Healthy Volunteers

Phase 1

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

CompletedNCT04535752

Annexon, Inc.Safety and Tolerability in Healthy Volunteers

Start: 2020-10-30End: 2021-06-26Updated: 2021-08-30

A Study of ANX009 in Adult Participants With Lupus Nephritis

CompletedNCT05780515

Annexon, Inc.Lupus Nephritis

Start: 2022-08-09End: 2023-10-31Updated: 2024-08-22

Related Papers

Safety, Tolerability, and Clinical Pharmacology of ANX009, an Inhibitory Antibody Fab Fragment Against C1q, Administered Subcutaneously to Healthy Volunteers

Blood2021-11-051 citations